Norma, a South Korean quantum computing company, has successfully validated its quantum AI algorithms using NVIDIA’s CUDA-Q platform, achieving significant performance gains in drug development. This milestone highlights the transformative potential of quantum AI in accelerating complex computational tasks.
Norma validates quantum AI algorithms on NVIDIA CUDA-Q platform.
Achieves up to 73x faster performance in drug development tasks.
Collaboration with Kyung Hee University Hospital for novel drug discovery.
Algorithms include QLSTM, QGAN, and QCBM for biotechnology applications.
CUDA-Q outperforms CPU-based methods by 60.14–73.32x in forward propagation.
Plans to expand quantum AI validation to healthcare, defense, and finance.
On September 1, 2025, Norma announced the successful validation of its quantum AI algorithms on NVIDIA’s CUDA-Q platform, achieving computational speeds up to 73 times faster than traditional CPU-based quantum simulators. The project, conducted in collaboration with Kyung Hee University Hospital at Gangdong, focuses on discovering novel drug candidates. “This project is a meaningful example of collaboration between domestic and international quantum technology companies and hospitals, showcasing the practical potential of quantum technologies,” said Hyunchul Jung, CEO of Norma.
Norma’s quantum AI algorithms, including QLSTM, QGAN, and QCBM, were tested in the CUDA-Q environment using NVIDIA H200 GPUs and GH200 Grace Hopper Superchips. The platform’s hybrid quantum-classical capabilities simplify GPU and QPU integration, enabling faster algorithm development. The results showed forward propagation of an 18-qubit quantum circuit was 60.14 to 73.32 times faster, and backward propagation was 33.69 to 41.56 times faster than CPU-based methods. The GH200 outperformed the H200, with 22% shorter forward propagation and 24% shorter backward propagation times.
Traditional AI approaches struggle with the vast chemical search space in drug discovery, often hitting computational limits. Norma’s quantum AI algorithms, designed for biotechnology, defense, and finance, overcome these barriers. By leveraging CUDA-Q’s superior performance, Norma reduced development costs and time, enabling faster and more realistic algorithm verification before deployment on quantum hardware. This advancement underscores the practical applicability of quantum AI in addressing complex industry challenges.
Norma plans to extend its quantum AI validation efforts into healthcare, defense, and finance, building on its collaboration with NVIDIA. “Through active technological cooperation with NVIDIA, we plan to continuously expand performance testing of quantum AI algorithms across a wide range of sectors, like healthcare,” said Hyunchul Jung. This positions Norma to lead in the growing quantum computing market, projected to reach $65 billion by 2030, driven by advancements in drug discovery and AI integration.
Norma’s validation of quantum AI algorithms on NVIDIA CUDA-Q marks a significant step toward revolutionizing drug development. By achieving up to 73x faster performance, the company demonstrates the power of quantum AI to transform industries, setting the stage for broader adoption of quantum technologies.
Norma is a quantum computing company based in Seoul, South Korea, focused on developing quantum AI algorithms for applications in biotechnology, defense, and finance. Led by CEO Hyunchul Jung, Norma collaborates with global technology leaders like NVIDIA and institutions like Kyung Hee University Hospital to advance quantum computing solutions.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.